The deliberations and conclusions of a Scottish multidisciplinary working group commissioned to review the current status of screening in Scotland and to develop future strategy are summarised in this booklet.
Like many other monographs on screening it deals with the generalities necessary to ensure that screening does more good than harm, and to carry out appropriate assessments of efficacy, safety, and costs. Half the text is concerned with the ethical, psychological, and economic aspects of screening, with a spectrum of viewpoints discussed. The conclusions here are broadly sensible. The issues are not explained with the comprehensiveness and clarity that some readers might seek (there is no discussion in the economics section on the appropriateness of discounting for example), but the committee did not intend this as a textbook.
The booklet goes on to identify many of the disorders that lend themselves to prevention through screening, but includes others that do not. What is lacking here is a quantitative assessment of the costs and benefits ofscreening. Many disorders are considered without making it clear exactly what the screening test would involve, whether there is a remedy, and whether the benefits would outweigh the costs. In the section on screening for colorectal cancer, for example, the Minnesota trial is cited, showing that annual faecal occult blood testing reduced mortality from colorectal cancer by one third. The committee clearly smelt a rat and was uncomfortable with the "too good to be true" aspect of this, but gave unconvincing reasons for not introducing screening despite this resultthe Minnesota population might be different from the British population, there might be psychological effects, etc. In fact the false positive rate was 10%: 38% of the treated subjects had at least one colonoscopy during the trial period, and annual faecal occult blood testing would necessitate 10% of the population having colonoscopies each year, surely the most important consideration to set against the introduction of screening.
The booklet -again like many other monographs on screening -is muddled on what may be termed "risk factor screening" -bone density, cholesterol, blood pressure, family history. Bone density (osteoporosis) screening is not recommended, but the authors temper this apparent rejection with a recommendation that "those at risk should be offered hormone replacement therapy" without specifying who is at risk, or for how long the therapy should be continued. They presumably have in mind women with early surgical menopause, patients taking steroid tablets, etc, but the booklet lacks authority in either specifying the necessary detail for doctors to carry out this recommendation, or, if this is not known, in making the ignorance explicit and recommending research that would tBke 'Patters forward.
Testing for heart disease risk factors is recommended as a halfway house -"during consultations in general practice". If such screening works a specific national policy should be started to ensure universal coverage at the appropriate interval. If screening does not work it should not be carried out at aU. And if we do not know whether screening works this should be stated explicitly and necessary research specified.
This confusion about measuring heart disease risk factors as screening tests is combined with uncertainty as to the value of lowering cholesterol. Did the panel really believe that "only in the small minority of people at very high risk do the benefits (reduced coronary heart disease monality) outweigh the adverse effects" of lowering cholesterol, and if they did should they advocate screening people at low and moderate risk for low cholesterol with a view to increasing it?
Other broad issues -such as school medical examinations, deafness -are considered only loosely, uncenainty as to their value is expressed, but methods of resolving the uncertainty are not discussed. The booklet ends with a "lifecycle stage" summary of screening tests available at different ages, which maintains this uncertainty and mixes in a great deal of primary prevention -immunisation, health education on cigarette smoking, drug abuse, safe sex, etc -essential measures but hardly screening.
Despite its indecisiveness on some of the scientific issues, the book summarises screening programmes that are currently thought to be wonhwhile and does highlight the degree ofuncenainty that surrounds other screening tests that are unproved or thought not wonhwhile. While it is true that there is still no accepted preventive policy, the fact that the use of combined oral contraceptives can reduce the risk of epithelial ovarian cancer by 50% or more must not be overlooked. This effect of oral contraceptives has been consistently shown in case-eontrol studies," cohort studies, 2 and analyses of vital statistical trends.' The reduction in risk increases with duration 57 oforal contraceptive use and persists for many years after discontinuation.
MALCOLM LAW
Analyses of the benefits and risks of oral contraceptive use generally suggest that the former outweigh the latter.' Perhaps serious consideration should now be given to recommending that all women without contraindications should take oral contraceptives for a few years at some time during their reproductive life. On the other hand, oral contraceptive use is now at such a high level in the United Kingdom, at least, that such a recommendation might prove superfluous. 
MPVESSEY

Survival and interim. end points in breast cancer
Sir: Reporting on survival analyses oftumours diagnosed in the UK breast screening trial, Moss IIf aJ' note that adjustment for tumour size and axillary lymph node status does not remove the difference in survival attributable to detection mode (first screen, subsequent screen, clinical, interval and cancers diagnosed in non-attenders). They further note the difference between these results and those from the Swedish two county trial, 2 and suggest that the UK results argue against the use of tumour attributes as interim end points in screening trials. It is likely, however, that the data available in the UK trial are re-Hazard ratios and 95% confidence interoals for detection modes of breasr rumours (a) in the UK trial, adjusred for size and node sraws (30% wirh node sraws missing); (b) in the Swedish fWO counry srudy, adjusted for size, node srarus, and grade; and (c) attributes, to have classifications available for (almost) all cases, and to include tumour grade or a similar "biologic" factor. Results should also be validated eventually by mortality data. It is our understanding that the British trial of breast screening frequency is paying careful anention to all these points. The Edinburgh component of the UK trial, which has a local randomised control group, records histological type for all operable tumours. A survival analysis of these data, currently being completed, will provide further insight into the role of tumour attributes, and the extent to which data from one country can predict the situation in another.
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COUfJJOld Road, Surron Sumry SM2 5NG Uniud Kingdom sponsible for the results, rather than nonstandardisation of prognostic factors or an inadequacy of tumour attributes as interim end points.
In the UK trial malignancy grade is not available and node status is missing in about 30% of cases. In the Swedish study node status is missing in only 4·5% of cases in the age group of the UK trial (45-64), and grade is adjusted for in addition to size and node status. Thus the adjustment for prognostic factors is considerably more complete in the Swedish two county study than in the UK trial. There is also evidence that creation of an extra category for missing values in adjustment, as seems to have been the practice in the UK trial, produces biased results.'
The table shows the hazard ratios of Moss et ail adjusted for size and node status, the hazard ratios from the Swedish two county study in the age group 45-64, considered by Moss et al, adjusted for size, node status, and malignancy grade, and the results arrived at from the Swedish study when only size and node status were adjusted for and a randomly selected 30% of the cases had node status receded to missing. The full adjustment in the Swedish data brings the hazard ratios much closer together than either the UK data or the partial adjustment in the Swedish data. The latter case is similar to the UK trial results. The full adjustment removes the difference in survival between interval cancers and incidence screen cancers, but as we noted before,' does not completely remove the better survival of prevalence screen cancers or the poorer survival of cancers in those who refuse screening.
These results indicate, firstly, that the difference between the Swedish and UK results is largely due to the more complete information in the Swedish study and, secondly, that the use of size, node status, and grade as interim end points is valid in certain designs of trial. In particular, the strategy is appropriate to the British trial of breast screening frequency (comparing annual with three yearly screening) in which there is no unscreened group, and from which prevalence screen cancers are excluded. 
Authors' reply
Day et aI suggest that the difference between the results of the survival analyses of the UK trial of early detection of breast cancer and the Swedish two counties trial may be largely attributable to missing data in the former. As we acknowledged in our paper, absence of information On tumour grade and the number of cases with missing data, particularly unknown dissemination status, was a cause for concern, though interestingly, there was no significant difference in adjusted survival between the two screening centres, despite very different percentages of unknown dissemination status. We also note that the Swedish results, even when adjusted for size, nodal status, and grade, are not inconsistent with those we report for the UK trial of early detection of breast cancer; for the most important comparison (later screens compared with controls) there is substantial overlap of the 95% confidence intervals for the hazard ratios. Our reason for treating unknown dissemination status and tumour size as separate categories was a belief that they were unlikely to be a random sample of cases. It was not possible to collect further information, but we did explore the alternative strategy of excluding all cases with missing data from the analysis. This resulted in a slightly lower hazard ratio in the multivariate analysis for cases detected at later (mammographic) screens but did not alter our conclusions.
Our primary aim in drawing comparisons between the two studies was to explore possible reasons for the different levels of reduction in breast cancer mortality observed. We believe, however, that the results provide important information about the use of interim end points in trials of screening, and imply the need for caution in their interpretation. In particular, it is clearly essential to have consistent reporting of tumour 
Opportunistic screening for abdominal aortic aneurysm
Sir: The conclusion of the study by Derbyshire er ai' that opportunistic screening of patients undergoing abdominal ultrasound for aneurysm is a cheap and effective proxy for a substantive screening programme is, in our view, not warranted for the following reasons.
The original premise that screening for abdominal aortic aneurysm (AAA) by ultrasound is effective has not been proved. Although a case has been made for devising a screening programme for AAA,' the usual criteria for an effective screening programme' are not fulfilled: the definition of AAA is not agreed, the indications for treatment and its outcomes are uncertain and, as the authors state in their discussion, the natural history of AAA is not known.
As a consequence the secondary aim of the study, to assess clinicians' knowledge, is of limited value. As the comparison is with the authors' own definition of good practice, which they admit is open to debate, no general conclusions can be drawn from the results.
Although starting an opportunistic programme of measuring abdominal aortic diameter may have no "discernible extra cost" to the radiography department, there would undoubtedly be additional costs to other parts of the NHS and to the patients. The paucity of information about the natural history of AAA means that some patients who are true positives by the current criteria may actually have an unnecessary major operation. For patients who are falsely positive there will be financial and social consequences in addition to the expected psychological morbidity in this group.' The authors extrapolate their examination rate and its findings to a hypothetical national programme, but it is unlikely that their patients are representative of those seen in other district general hospitals, or that many such hospitals would be able to provide the same level of radiological expertise.
